Currently out of the existing stock ratings of Jeff Jones, 135 are a BUY (97.83%), 3 are a HOLD (2.17%).

Jeff Jones

Work Performance Price Targets & Ratings Chart

Analyst Jeff Jones, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 45.83% that have a potential upside of 95.27% achieved within 159 days.

Jeff Jones’s has documented 256 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ALMS, Alumis Common Stock at 02-Sep-2026.

Wall Street Analyst Jeff Jones

Analyst best performing recommendations are on FUSN (FUSION PHARMACEUTICALS ).
The best stock recommendation documented was for CLRB (CELLECTAR BIOSCIENCES) at 11/19/2024. The price target of $12 was fulfilled within 22 days with a profit of $36.3 (75.16%) receiving and performance score of 34.16.

Average potential price target upside

ALMS Alumis Common Stock AVBP ArriVent BioPharma, Common Stock CATX Perspective Therapeutics CLRB Cellectar Biosciences CMMB Chemomab Therapeutics Ltd DRC CRBP Corbus Pharmaceuticals CRVS Corvus Pharmaceuticals EVH Evolent Health FUSN Fusion Pharmaceuticals  IMCR Immunocore Holdings Ltd KYMR Kymera Therapeutics MCRB Seres Therapeutics PLRX Pliant Therapeutics  PMVP Pmv Pharmaceuticals  RAIN Rain Therapeutics RXDX Prometheus Biosciences VBLT Vascular Biogenics Ltd VTYX Ventyx Biosciences YMAB Y mAbs Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 23-Jul-2024

$29

$17.9 (161.26%)

$38

Buy Since 25-Jul-2025

$25

$13.9 (125.23%)

$51

Buy Since 30-Jan-2025

$37

$25.9 (233.33%)

$55

Show more analysts

Please expand the browser size to see the chart

Which stock is Jeff Jones is most bullish on?

Potential upside of $42.75 has been obtained for CRBP (CORBUS PHARMACEUTICALS)

Which stock is Jeff Jones is most reserved on?

Potential downside of $18.61 has been obtained for CRVS (CORVUS PHARMACEUTICALS)

What Year was the first public recommendation made by Jeff Jones?

On 2021

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?